We examined the efficacy and safety of rituximab in patients with refractory systemic lupus erythematosus (SLE).
Methods
The study enrolled 63 SLE patients who were treated with rituximab between 2002 and 2015. The participants underwent a battery of tests before treatment and at one year. Treatment ranged from two to four times at 500 or 1000 mg.
Results
Baseline characteristics were males:females = 6:57, age 33.9 years, and disease duration 87.2 months. The primary endpoint: The rate of major clinical response (MCR) was 60% while the partial clinical response (PCR) was 25%. Thirty of 36 (83%) patients with lupus nephritis (WHO II: 2, III: 5, IV: 22, V: 4, IV+V: 2, not assessed: 1) and 22 of 24 patients (92%) with neuropsychiatric SLE, who could be followed at one year, showed changes from BILAG A or B score to C or D score at one year. Multivariate analysis identified high anti-dsDNA antibody and shorter disease duration as significant determinants of MCR at one year. Repeat examination was conducted at five years. Primary failure was recorded in 8.8% and secondary failure in 32.4% (time to relapse: 24.4 months). Rituximab was well tolerated although 65 adverse events, mostly infections, were recorded within one year.
Conclusion
Rituximab is potentially efficacious for the treatment of patients with refractory SLE.
LateefAPetriM. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther2012; 14(Suppl 4): S4–S13.
4.
Dall'EraMChakravartyEF. Treatment of mild, moderate, and severe lupus erythematosus: Focus on new therapies. Curr Rheumatol Rep2011; 13: 308–316.
5.
TokunagaMFujiiKSaitoKet al.Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford)2005; 44: 176–182.
6.
TanakaY. B cell-targeting therapy using anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Intern Med2007; 46: 1313–1315.
7.
TanakaYYamamotoKTakeuchiTet al.A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol2007; 17: 191–197.
8.
TanakaYTakeuchiTMiyasakaNet al.Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus including lupus nephritis who are refractory to conventional therapy. Mod Rheumatol2016; 26: 80–86.
9.
LeandroMJEdwardsJCCambridgeGEhrensteinMRIsenbergDA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum2002; 46: 2673–2677.
10.
LuTYNgKPCambridgeGet al.A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum2009; 61: 482–487.
11.
JónsdóttirTGunnarssonIMourãoAFLuTYvan VollenhovenRFIsenbergD. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: Pooled data from two cohorts. Rheumatology (Oxford)2010; 49: 1502–1504.
12.
MelanderCSalléeMTrollietPet al.Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol2009; 4: 579–587.
13.
MerrillJTNeuweltCMWallaceDJet al.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum2010; 62: 222–233.
14.
RovinBHFurieRLatinisKet al.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum2012; 64: 1215–1226.
15.
TewGWRabbeeNWolslegelKet al.Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus2010; 19: 146–157.
16.
HahnBHMcMahonMAWilkinsonAet al.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken)2012; 64: 797–808.
17.
BertsiasGKTektonidouMAmouraZet al.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis2012; 71: 1771–1782.
18.
IsenbergDARahmanAAllenEet al.BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford)2005; 44: 902–906.
19.
BencivelliWVitaliCIsenbergDAet al.Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol1992; 10: 549–554.
20.
IwataSSaitoKTokunagaMTanakaY. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis2012; 71: 1749–1750.
21.
ReadyVJayneDCloseDIsenbergD. B-cell depletion in SLE: Clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther2013; 15(Suppl 1): S2.
22.
MurphyGLisnevskaiaLIsenbergD. Systemic lupus erythematosus and other autoimmune rheumatic diseases: Challenges to treatment. Lancet2013; 382: 809–818.
23.
TerrierBAmouraZRavaudPet al.Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum2010; 62: 2458–2466.
24.
Díaz-LagaresCCrocaSSangleSet al.Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev2012; 11: 357–364.
25.
WeidenbuschMRömmeleCSchröttleAAndersHJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant2013; 28: 106–111.
26.
MurrayEPerryM. Off-label use of rituximab in systemic lupus erythematosus: A systematic review. Clin Rheumatol2010; 29: 707–716.
27.
Ramos-CasalsMSotoMJCuadradoMJKhamashtaMA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus2009; 18: 767–776.
28.
AguiarRAraújoCMartins-CoelhoGIsenbergD. Use of rituximab in systemic lupus erythematosus: A single center experience over 14 years. Arthritis Care Res (Hoboken)2017; 69: 257–262.
EzeonyejiANIsenbergDA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen. Rheumatology (Oxford)2012; 51: 476–481.
31.
LightstoneL. Minimising steroids in lupus nephritis—will B cell depletion pave the way?Lupus2013; 22: 390–399.
32.
Rodríguez-BayonaBRamos-AmayaAPérez-VenegasJJRodríguezCBrievaJA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther2010; 12: R108.
33.
AnolikJHBarnardJCappioneAet al.Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum2004; 50: 3580–3590.
34.
SanzIWeiCLeeFEAnolikJ. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol2008; 20: 67–82.
35.
JacobiAMReiterKMackayMet al.Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum2008; 58: 1762–1773.
36.
WeiCAnolikJCappioneAet al.A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol2007; 178: 6624–6633.
37.
JacobiAMOdendahlMReiterKet al.Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum2003; 48: 1332–1342.
38.
IwataSSaitoKTokunagaMet al.Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol2011; 38: 633–641.
39.
IwataSTanakaY. B cell subsets, signaling and their roles in secretion of autoantibodies. Lupus2016; 25: 850–856.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
